The case for combined-modality therapy for limited-stage Hodgkin's disease

Oncologist. 2012;17(8):1006-10. doi: 10.1634/theoncologist.2012-0148. Epub 2012 Jul 17.

Abstract

Results of the Hodgkin's Disease.6 trial are critically examined in light of the advances in radiation therapy techniques that have occurred since it was initiated. The ultimate findings of the HD.6 trial do not close the case for combined-modality treatment of limited-stage Hodgkin's disease.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / radiotherapy*
  • Humans
  • Meta-Analysis as Topic*
  • Neoplasm Staging